The nation of Zimbabwe has rejected a substantial American healthcare agreement worth $367m (£272m) spanning five years because of Washington's demand for confidential data.
The decision came to light after a official document dated December was leaked, revealing that President Emmerson Mnangagwa deemed the agreement was "unbalanced".
An official representative later stated that the US was demanding access to genetic material for research and commercial purposes but refused to share the resulting advantages from any future medical innovations.
"We are forced to start the challenging and unfortunate process of ending our health assistance in Zimbabwe," stated American envoy to Zimbabwe Pamela Tremont in a statement.
Her embassy indicated the US had provided over $1.9bn for health programmes to Zimbabwe over the last twenty years.
A doctors' association in Zimbabwe has called for further negotiations to secure a deal agreeable to both sides so the nation's vital HIV programme can proceed.
Wider Background
This rejection follows a similar situation in Kenya, where a court halted a similar health funding agreement after concerns were raised about the safety of Kenyans' health data.
After resuming the presidency last year, US President Donald Trump has drastically cut overseas assistance and closed the key foreign aid agency.
USAID had overseen aid for the American government, but Trump argued its expenditure was "inefficient" and his government was seeking government-to-government agreements to boost transparency and accountability.
According to reports, Sixteen African countries have so far signed similar health pacts, constituting over $18.3bn in committed funds.
Details of the Declined Agreement
This assistance for Zimbabwe would have supported "tackling HIV/Aids, tuberculosis, malaria, maternal and child health, and disease outbreak preparedness.
"We believe this partnership could have provided immense benefits for the people of Zimbabwe, particularly the 1.2 million presently on antiretroviral therapy through American-funded programmes," Tremont added.
However, official spokesman Nick Mangwana argued the arrangement was "unequal".
"Zimbabwe was being asked to share its biological resources and data indefinitely, with no equivalent guarantee of access to any medical innovations – like vaccines, diagnostics, or treatments – that might result from that provided information," his statement read.
"Effectively, our country would provide the raw materials for scientific discovery with no certainty that the resulting innovations would be available to our population if a new pandemic emerge."
National Interest and International Frameworks
Mangwana further pointed out that the American exit from the global health body and its push of bilateral health agreements were undermining systems already established via the global organization.
Mangwana cited its Pathogen Access and Benefit Sharing scheme designed to deal with future pandemics.
"This system is designed to ensure that when a country provides its samples, the resulting advantages – such as medicines and cures – are shared equitably, not commercialised solely by those with the resources to create them."
The government's concerns over the US deal "must not be interpreted as hostility towards the US," he added.
"We encourage ongoing dialogue with our American counterparts on how subsequent co-operation could be structured in a manner that respects the independence and interests of each country."
Medical Community Reaction
Medical experts said it acknowledged the government's concerns, but recommended that negotiations should continue considering much of the nation's Aids initiatives depended on external financing.
"If technical issues arise, such as those relating to data governance or agreement terms, these can often be resolved via technical clarification and negotiated safeguards," the group said.
The halted deal highlights the complex tensions between accepting vital international aid and safeguarding national sovereignty in an increasingly data-driven world.